[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 547,641,856
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,659 M
  • EBITDA $ 31,162 M
  • 60-Month Beta 0.34
  • Price/Sales 5.89
  • Price/Cash Flow 16.34
  • Price/Book 6.84

Options Overview Details

View History
  • Implied Volatility 23.45% (+0.09%)
  • Historical Volatility 16.39%
  • IV Percentile 87%
  • IV Rank 63.12%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 3) 4.22 (1.87%)
  • Put/Call Vol Ratio 0.62
  • Today's Volume 10,421
  • Volume Avg (30-Day) 20,540
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 333,626
  • Open Int (30-Day) 357,509
  • Expected Range 221.12 to 229.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 8
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
223.77 +0.70%
on 04/22/26
247.21 -8.85%
on 04/02/26
-15.11 (-6.28%)
since 03/27/26
3-Month
223.77 +0.70%
on 04/22/26
251.71 -10.48%
on 03/02/26
+0.90 (+0.40%)
since 01/27/26
52-Week
146.12 +54.22%
on 05/14/25
251.71 -10.48%
on 03/02/26
+70.76 (+45.78%)
since 04/25/25

Most Recent Stories

More News
Johnson & Johnson to Participate in the Bernstein’s 42nd Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 42 nd Annual Strategic Decisions Conference on Wednesday, May 27 th , 2026. Management will participate in a...

JNJ : 225.34 (-0.95%)
FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which...

JNJ : 225.34 (-0.95%)
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+

JNJ : 225.34 (-0.95%)
Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 th . Management will participate in a Fireside Chat at 11:30...

JNJ : 225.34 (-0.95%)
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilities i to electrophysiology ...

JNJ : 225.34 (-0.95%)
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4%

Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.

COST : 998.01 (-1.30%)
KO : 75.44 (-1.55%)
JNJ : 225.34 (-0.95%)
ACI : 16.57 (-0.30%)
PG : 148.40 (+0.15%)
LLY : 868.27 (-1.77%)
Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now

Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation

HRL : 21.47 (-0.37%)
JNJ : 225.34 (-0.95%)
KVUE : 17.53 (+0.23%)
O : 62.75 (-0.92%)
Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will present at the Bank of America 2026 Healthcare Conference on Tuesday, May 12 th , 2026. Management will participate in a Fireside Chat at 2:20 p.m. Eastern...

JNJ : 225.34 (-0.95%)
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

JNJ stock is on track to rally higher after better-than-expected results. Cash flow and growth say this dividend story is reliable.

JNJ : 225.34 (-0.95%)
Stock Index Futures Gain on Hopes for Renewed U.S.-Iran Talks, PPI Data and More Big Bank Earnings on Tap

June S&P 500 E-Mini futures (ESM26) are up +0.19%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.39% this morning as risk appetite improved and oil prices fell following reports that the U.S. and...

BLK : 1,056.86 (+1.14%)
C : 129.14 (+0.91%)
BE : 234.68 (+1.52%)
SNDK : 1,070.20 (+8.11%)
CRDO : 180.50 (-7.45%)
JPM : 311.63 (+1.09%)
JNJ : 225.34 (-0.95%)
HPQ : 19.76 (-0.15%)
MU : 524.56 (+5.60%)
ORCL : 172.96 (-0.18%)
ESM26 : 7,199.25 (-0.09%)
MSFT : 424.82 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 230.94
2nd Resistance Point 229.42
1st Resistance Point 227.38
Last Price 225.34
1st Support Level 223.83
2nd Support Level 222.31
3rd Support Level 220.27

See More

52-Week High 251.71
Last Price 225.34
Fibonacci 61.8% 211.37
Fibonacci 50% 198.91
Fibonacci 38.2% 186.45
52-Week Low 146.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.